앱클론은 CAR-T세포치료제 센터를 본격 구축하기 위해 140억원 규모의 전환우선주를 발행하기로 결정했다고 15일 밝혔다.
Abclon made an announcement on the 15th that it has decided to issue KRW 14 billion worth of convertible preferred stocks to build a CAR-T cell therapy center in earnest.